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Abstract
Objective—Uncontrolled HIV infection progresses to the depletion of systemic and mucosal 
CD4 and AIDS. Early HIV infection may be associated with increases in the concentration of 
MIP-3α in the blood and gut fluids. MIP-3α/CCL20 is the only chemokine known to interact with 
CCR6 receptors which are expressed on immature dendritic cells and both effector and memory 
CD8+ and CD4+ T cells. The role and prognostic value of blood levels of MIP-3α in HIV-infected 
individuals has yet to be described.
Methods—We determined the serum levels of MIP-3α, and IFN-γ, in 167 HIV-1-infected and 27 
HIV-1-uninfected men participating in the Multicenter AIDS Cohort Study (MACS). The blood 
biomarkers were measured using enzyme-linked immunosorbent assays (ELISA) and the cell 
phenotypes using flow cytometry.
Results—Median serum levels of MIP-3α in HIV-1-infected and uninfected men was 
significantly different (p<0.0001) and were 21.3 pg/mL and 6.4 pg/mL respectively. The HIV-1-
infected men with CD4+ T cell count <200 cells/μL showed the highest median serum MIP-3α 
(23.1 pg/mL). Serum levels of MIP-3α in HIV-1 infected (n=167) were negatively correlated with 
absolute number of CD4+ T cell (p=0.01) and were positively correlated with CD38 molecules on 
CD8+ T cells (p=0.0002) and with serum levels of IFN-γ (0.006).
Conclusion—Serum levels of MIP-3α concomitantly increase with plasma levels of IFN-γ, 
CD38 expression on CD8+ T cells, and decreased of absolute CD4+ T cells in HIV-1-infected men. 
A higher blood level of MIP-3α may be representation of locally high level of MIP-3α and more 
recruitment of immature dendritic cell at site of infection. Involvement of CCR6/CCL20 axis and 
epithelial cells at the recto-colonel level may enhance sexual transmission of HIV-1 in MSM and 
may be useful as a prognostic marker in HIV-1-infection and AIDS.
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Introduction
Chemokines are small polypeptides (90-130 amino acids) that regulate cellular activation, 
chemotaxis, leukocyte trafficking, and cellular adhesion. There are approximately 40-50 
currently known human chemokines that are divided into two subfamilies (CXC and CC) 
with more than 20 receptors [1-4]. The CXC subfamily is further divided into ELR-CXC 
and non-ELR-CXC chemokines depending on the presence of a tripeptide (Glu-Leu-Arg) 
ELR-motif preceding the first cysteine residue [5].
One of the novel members of the CC chemokines is known as liver activation regulated 
chemokine (LARC) [6], Exodus-1 [7], macrophage inflammatory protein-3α [8], and has 
been classified as a CCL20 chemokine [9]. MIP-3α is the only chemokine that has high 
specificity for the chemokine receptor, CCR6 [10-13], which is expressed on several human 
cell types implicated in HIV infection, including immature dendritic cells (iDCs) [14], 
effector/memory CD8+ and CD4+ T cells [15,16], and interleukin-17 (IL-17) producing T 
cells (TH17).
CCR6 is highly expressed on peripheral blood CD4+ CCR5+ memory T cells and two 
populations of CD4+ T cells within the gut (α4β7+ T and TH17 cells) that are highly relevant 
to HIV-1-infection [17,18]. CCR6 is an independent HIV/SIV co-receptor may promote HIV 
transmission and disease progression in part, when other major co-receptors are affected 
[19]. CCL20/MIP-3α is responsible for the chemo-attraction of iDCs, effector/memory B 
cells and T cells. CCL20/MIP-3α has also been shown to be chemotactic for CD11b+ 
myeloid DCs in the Peyer's patch, and is involved in the regulation of humoral immunity and 
lymphocyte homeostasis.
Human β-defensin 2 and CCL20/MIP-3α both exhibit antimicrobial and anti-HIV activity 
that is mediated by induction of the host restriction factor apolipoprotein B mRNA-editing 
enzyme-catalytic ploypeptide-like 3G (APOBEC3G) [20]. Many chemokines, including 
CCL20/MIP-3α, show antimicrobial capability in vitro [21]. Studies have suggested that the 
production of CCL20/MIP-3α by epithelial cells is an important component of the innate 
immune defense in the female reproductive tract [22]. Berliner et al., demonstrated that 
human seminal plasma is able to stimulate human vaginal epithelial cells and cause the 
secretion of CCL20/MIP-3α, leading to the enhanced recruitment of Langerhans cell 
precursors to the area, acting as a possible path for HIV transmission in heterosexual 
individuals [23].
It has been recently shown that iDC (CD1a+ CD86−) and mature DC (CD1a+ CD86+) 
exclusively responded to CCL20/MIP-3α and CCL19/MIP-3β respectively, and that the 
number of CCR6 receptors for CCL/20MIP-3α decreases as iDCs mature DCs [24].
DCs are effective antigen presenting cells that are distributed throughout the skin and 
mucosal surfaces. Upon exposure to HIV-1, DCs process and present antigens to immune 
cells for further complex action. Furthermore, DCs may carry live HIV and may secondarily 
infect T-cells in lymph nodes. During this process the DCs and T-cells could be lost by direct 
lysis or by the action of specific cytotoxic T cells (CTLs) [25].
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CCL20/MIP-3α is also a potent adjuvant in augmenting CTLs that provide strong protection 
in immunized animals against challenge with the vaccinia virus expressing the gag protein 
[26]. The role of CCR6 and its ligand has also been studied in a variety of diseases and may 
contribute to disease pathogenesis via autocrine and/or paracrine mechanisms [27-37].
Although DCs are known to play an important role in HIV-1 pathogenesis, the role of 
MIP-3α/CCL20 as a local and systemic player in HIV-1 infected individuals is poorly 
understood. Measurement of CCL20/MIP-3α in local microenvironments such as the gut is 
a challenging task. Thus, we examined CCL20/MIP-3α concentrations in the blood and 
found a correlation with markers of immune activation in HIV-1-infected men. We speculate 
that this may reflect the concentrations and the action of the MIP-3α/CCL20 at local sites.
Materials and Methods
Specimens
Serum samples from HIV-1-infected and HIV-1-uninfected men participating in the 
Multicenter AIDS Cohort Study (MACS) of the Natural History of AIDS at UCLA were 
selected based on the absolute CD4+ T cell counts (<200, 200-400, and >400 cells/μl) [38]. 
The institutional review board for human studies at UCLA approved the protocols and blood 
samples were obtained after informed consent. Blood was collected into 10 ml (Becton 
Dickinson VACUTAINER Systems, New Jersey) plain plastic tubes without anticoagulant 
for obtaining serum. Serum was separated and stored at −70°C until batch testing.
CCL20/MIP-3 α assay
Concentrations were measured using a sandwich enzyme immunoassay from R&D Systems 
(Minneapolis, MN, USA). The lower limit of detection was 9.0 pg/mL and the intra-assay 
coefficient of variation (CV) was determined to be 14.2% and 3.4% for control samples with 
mean concentrations of 57.3 pg/mL (n=12) and 279.0 pg/mL (n=12), respectively.
Interferon gamma (IFN-γ)
Concentrations were measured using a sandwich enzyme immunoassay from Beckman 
Coulter (Brea, CA, USA). The lower limit of detection was 10 U/L and the intra-assay CV 
was determined to be 16.5%, 6.4%, and 11.1% for control samples with mean 
concentrations of 47U/L (n=10), 249.7 U/L (n=10), and 3665 U/L (n=10) respectively.
Flow cytometry
Immunophenotyping and quantification of CD38 molecules on CD8+ T cells was performed 
using a FACSCalibur flow cytometer (Becton Dickinson, CA, U.S.A.) as previously 
described [39,40].
Statistical analysis
A four-parameter curve-fitting program (Bio-Rad Laboratories, Irvine, CA) was used to 
generate calibration curves for each enzyme immunoassay.
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Descriptive statistics were used to illustrate the blood markers among study groups. Two-
sample t-tests were applied to compare CCL20/MIP-3α concentrations between two study 
groups. Log10 transformations were applied when normal distribution assumption was not 
demonstrated. Spearman corrections were utilized to assess the association between two 
blood markers. Data were analyzed using SAS version 9.4 (SAS Institute, 2013). Graphs 
were produced by using SigmaPlot software version 11 (Jandel Scientific, San Rafael, CA 
2008).
Results
Median serum concentrations of CCL20/MIP-3α in HIV-1-uninfected and HIV-1-infected 
men was 21.3 pg/mL (n=167) and 6.4 pg/mL (n=27), respectively (Figure 1). CCL20/
MIP-3α concentrations were significantly (p<0.0001) higher for HIV-1-infected men when 
compared with HIV-1-uninfected men. The median serum concentration of CCL20/MIP-3α 
in HIV-1-infected men with CD4+ T cell counts <200 cells/μL was 23.1 pg/mL (n=61); in 
HIV-1-infected men with CD4+ T cell counts of 200–400 cells/μL it was 19.6 pg/mL (n=53); 
and in HIV-1-infected men with CD4+ T cell counts >400 cells/μL it was 19.7 pg/mL 
(n=53), respectively (Figure 1). Concentrations of CCL20/MIP-3α were significantly higher 
in HIV-1-infected men with CD4+ T cell counts <200 cells/μL compared to the men with 
CD4+ T cells counts ranging from 200–400 cells/μL (p=0.0144) and >400 cells/μL 
(p=0.0052). There was no difference between mean concentrations of CCL20/MIP-3α when 
comparing HIV-1-infected men with CD4+ T cell counts of 200–400 cells/μL and with 
CD4+ T cell counts >400 cells/μL.
The median, mean, standard deviation and ranges for HIV-1 RNA (viral load), white blood 
cell counts (WBC), lymphocyte percentage, CD38 molecules on CD8+ T cells, MIP-3α, and 
IFN-γ serum concentrations according to the three CD4 groups (<200, 200–400 and >400 
cells /μL) are presented in Table 1.
The correlation coefficients between serum concentrations of MIP-3α and WBC counts , 
percentage of lymphocytes, CD38 molecules on CD8+ T cells, IFN-γ, and HIV viral load 
for HIV-1-infected according to CD4+ T cell counts listed in Table 2.
Discussion
Dendritic cells stimulate protective immunity, play a secondary role in HIV infection, and 
have also been known for their function as a “Trojan horse” on the HIV infection course 
[41]. MIP-3α may play a crucial role in the formation and function of the axis of the 
HIV→iDCs-CCR6←CCL20 during sexual transmission of HIV infection at the local site of 
the mucosal lymphoid tissues by attracting iDCs and T-cells toward epithelial cells. Song et 
al. have shown that intramuscular inoculation of pMIP-3α, alongside recruitment of more 
iDCs to the injection site, also enhances DC function [26].
It is well known that the sexual transmission of HIV-1 requires a small amount of virus at a 
mucosal site of inoculation to gain access to the cells that are permissive for the HIV-1 viral 
infection [42,43]. iDCs are constantly sampling their environment for foreign antigens, they 
capture theses antigens, and leave the tissue carrying the antigen to the lymph nodes and 
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progress into mature DCs. In addition, human seminal plasma is able to stimulate the vaginal 
or recto-colonic epithelial (Langerhans cells) and sub epithelial cells to secrete more 
MIP-3α/CCL20 [23] for further recruitment of iDCs to the local site for encounters with 
virus. Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-
SIGN) at the local site can capture HIV-1 and promote infection of permissive cells in Trans-
infection [44].
CCR6/MIP-3α and CCR7/MIP-3β play a major role in the constitutive trafficking of 
peripheral DCs along lymphatic channels to the outer surface of lymph nodes in SIV 
infection and this could play this role for HIV-1 infection in humans as well [45].
The potential mechanism of MIP-3α as part of CCR6/MIP-3α axis in the development of 
sexual transmission of HIV infection is summarized in a diagram (Figure 2).
The aim of our study was to investigate the relationship between the blood level of MIP-3α 
and local recruitments of iDC as a prognostic tool by correlating blood levels of MIP-3α 
with IFN-γ, viral RNA, and CD38 molecules on CD8+ T cell as an activation marker.
We found that the serum levels of MIP-3α were significantly elevated in HIV-1-infected 
men compared with HIV-1-uninfected men (p<0.0001). The serum levels of MIP-3α were 
significantly higher in HIV-1/AIDS compared to HIV-1 with absolute CD4+ T cell counts of 
200-400 and >400 cells/μL. This relatively high blood concentration of MIP-3α may 
contributes to higher local recruitments of iDCs and poor prognoses in patients. Fontaine et 
al. also have shown above normal plasma levels of MIP-3α in both normal and rapid 
progressor of HIV-1-infected individuals [46].
Serum levels of MIP-3α in all HIV-1-infected cases exhibited positive correlations with 
CD38 molecules on CD8+ T cells and IFN-γ (Figures 3a and 3b), negative correlation with 
lymphocyte and absolute CD4+ T cells count (0.015) but were not correlated with number of 
WBC, and HIV RNA (Table 2).
Among HIV-1-infected men with CD4+ T cell counts <200 cells/μL, MIP-3α showed 
negative correlation with lymphocytes and positively correlation with CD38 molecules on 
CD8+ T-cells (Figures 3c and 3d), but was not correlated well with plasma levels of HIV 
RNA (p=0.051) which may be due to the effect of antiretroviral therapy on the plasma level 
of HIV RNA but not in the viral reservoir sites.
Studies have shown that the plasma level of HIV RNA correlates well with immune 
activation markers during HIV-1 infection and antiretroviral therapy, but in some cases these 
relationships may not be constant and strong such as we observed in our study between HIV 
RNA and MIP-3α for HIV-1-infected men with CD4+ T cell<200 cells/μL. In addition, high 
levels of MIP-3α with increased expression of CD38 molecule on CD8+ T cell may be an 
indication of the HIV persisting in a patient's viral reservoir tissues, and the MIP-3α in 
combination with other markers could be a useful prognostic test in those cases.
Since the T cell activation marker of CD38 molecules on CD8+ T cells is strongly correlated 
with blood levels of MIP-3α we may be able to use the blood level of MIP-3α as a surrogate 
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marker for local levels of MIP-3α which therefore could also serve as an activation marker 
for iDC. Ye Ping et al. demonstrated that there were no significant differences among the 
four clinical stages of HIV-1 infection in the serum levels of CC-chemokines [47] and we 
also observed no significant differences among the two groups of patients with CD4+ T cell 
between 200-400 cells/μL and CD4+T cell> 400 cells/μL for MIP-3α. The weakness of our 
study is that the levels of MIP-3α have not been explored and measured in the fluid at the 
recto-colonel level.
In conclusion, the blood levels of MIP-3α in HIV-1-infected men with CD4+ T cell<200 
cells/μL and all HIV-1-infected cases positively correlated with CD38 molecules expression 
on CD8+ T cell. The high levels of MIP-3α in HIV/AIDS may contribute to the recruitment 
of more iDC and other immune cells at the local site of the infection particularly the recto-
colonel site of men who have sex with men (MSM) which may cause increased immune 
activation triggering a poor prognosis of HIV-1-infected patients. This finding could be a 
base for further investigations on the role and regulation of MIP-3α in the pathogenesis of 
HIV-1, especially at the recto-colonel region.
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Figure 1. 
log10 transformed serum concentrations of CCL20/MIP-3α in HIV-1 negative men and 
HIV-1 positive men with CD4+ T cell counts <200, between 200 and 400 and >400 cells/μL. 
The solid lines represent the median and the box represents the 25th to 75th percentiles. 
Individual outlying data points are presented as filled black circles.
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Figure 2. 
Role of CCR6/MIP-3α axis in sexual transmission and progression to HIV-1 infection.
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Figure 3. 
Positive correlation between log10 transformed serum concentrations of CCL20/MIP-3α and 
log10 transformed of IFN-γ (a), positive correlation with log10 transformed of number of 
CD38 molecules on CD8+ T cells (b) shown all HIV-1-infected in the study. Negative 
correlation between log10 transformed serum concentrations of CCL20/MIP-3α and 
percentage of lymphocyte (c) and positive correlation with log10 transformed of number of 
CD38 molecules on CD8+ T cells(d) shown for HIV-1-infected men with CD4+ T cell 
counts <200 cell/μL.
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Table 1
Blood concentrations of markers for HIV-1 infection stratified according to CD4 cell counts.
CD4* T-Cell Count/μL
Markers <200 n=61 200-400 n=53 >400 n=53
$Viral load (copies/mL)
Median (range) 4,750 (0–948,000) 248 (0-172,000) 98 (0-184,669)
Mean (SD) 77,631 (±167,658) 13,804 (±30,593) 18,124(± 40,709)
WBC count (× 103/μL)
Median (range) 4.1 (1.2–9.2) 5.2 (2.2–12.6) 5.1 (2.6–8.8)
Mean (SD) 4.2 (± 1.76) 5.3 (± 1.81) 5.4 (± 1.36)
Lymphocyte (%)
Median (range) 27.0(1–64) 34 (12–53) 39 (18–63)
Mean (SD) 28.7 (± 13.42) 34 (± 9.76) 38(± 9.78)
*CD38 on CD8 cells
Median (Ranges) 2,623 (143-18,543) 1,412 (197–10,815) 1017 (175–10,879)
Mean (SD) 4,312 (±4,304) 1,781 (± 1,781) 1,667 (± 2,045)
MIP-3α (pg/mL)
Median (Ranges) 23.1 (5.4-726) 19.6 (3.9-222) 19.7 (3.4–302)
Mean (SD) 71.2 ( ± 128) 27.8 (± 33) 26.8 (± 41)
IFN-γ (U/L)
Median (Ranges) 96 (0-907) 52 (5–636) 74(0–294)
Mean (SD) 169 (± 203) 95 (± 122) 90 (± 74)
$Viral load=HIV RNA
*
expression of CD38 molecule
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Table 2
Correlation coefficient between serum levels of MIP-3α and markers. Significant between markers have 
shown as bold font.
Groups WBC Lymphocytes CD38 on CD8 IFN-γ HIV-1 RNA
All cases 0.11885* −0.17731 0.29289 0.23386 0.13871
0.126φ 0.0219 0.0002 0.0063 0.0883
167n 167 156 135 152
CD4<200 0.26616 −0.28791 0.49085 0.27244 0.27455
0.0381 0.0244 0.0003 0.0670 0.0512
61 61 51 46 51
CD4=200-400 0.09355 −0.11102 0.15913 0.24936 −0.04706
0.5052 0.4287 0.2598 0.0718 0.7455
53 53 52 53 50
CD4>400 0.15268 0.03114 0.05899 0.02401 −0.00493
0.2751 0.8248 0.6748 0.8894 0.9726
53 53 53 36 51
*Spearman correlation coefficient
φp value
n
number of men
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